Stocktoria
Immunovant, Inc. IMVT
Nasdaq · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2019-05-14
Immunovant, Inc. financials (annual)
Bars are annual figures from 2019 to 2026; red bars are negative (a loss or cash outflow).
| Metric | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| R&D expense | — | — | — | — | $101.8M | $68.6M | $47.9M | $25.7M |
| Interest expense | — | — | — | — | — | $0 | $625,000 | — |
| Income tax | $215,000 | $891,000 | $567,000 | $9,000 | -$84,000 | -$358,000 | $97,000 | $19,000 |
| Net income | -$505.6M | -$413.8M | -$259.3M | -$211.0M | -$156.7M | -$107.4M | -$66.4M | -$28.6M |
| EPS (diluted) | $-2.77 | $-2.73 | $-1.88 | $-1.71 | $-1.43 | $-1.22 | — | — |
| Operating cash flow | -$407.3M | -$375.9M | -$214.2M | -$188.2M | -$106.1M | -$83.3M | -$53.4M | -$28.5M |
| Free cash flow | -$407.3M | -$376.6M | -$214.6M | -$188.4M | -$106.4M | -$83.5M | -$53.4M | -$28.6M |
| Cash & equivalents | $902.1M | $714.0M | $635.4M | $376.5M | $493.8M | $400.1M | $100.6M | $7.0M |
| Total assets | $957.0M | $776.2M | $666.4M | $405.8M | $515.6M | $412.5M | $109.4M | $13.8M |
| Total liabilities | $104.4M | $68.8M | $48.6M | $43.3M | $45.7M | $21.0M | $15.3M | $6.5M |
| Shareholders' equity | $852.6M | $707.4M | $617.8M | $362.5M | $469.8M | $391.5M | $94.1M | $7.3M |
Computed from company filings · US · as of 2026-03-31. Facts plus Stocktoria's own computed scores — not investment advice.